Preparation of von Hippel-Lindau (VHL) E3 ubiquitin ligase ligands exploiting constitutive hydroxyproline for benzylic amine protection

被引:0
|
作者
Soto-Martinez, Diana M. [1 ]
Clements, Garrett D. [1 ]
Diaz, John E. [1 ]
Becher, Joy [1 ]
Reynolds, Robert C. [2 ]
Ochsenbauer, Christina [2 ]
Snowden, Timothy S. [1 ,3 ]
机构
[1] Univ Alabama, Dept Chem & Biochem, 250 Hackberry Lane, Tuscaloosa, AL 35487 USA
[2] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
[3] Univ Alabama, Ctr Convergent Biosci & Med, 720 2nd St, Tuscaloosa, AL 35401 USA
基金
美国国家卫生研究院;
关键词
DEGRADER; IDENTIFICATION; POMALIDOMIDE; BOROHYDRIDE; PRECATALYST; COMPLEXES; NHC;
D O I
10.1039/d4ra01974a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The von Hippel-Lindau (VHL) protein serves as the substrate recognition subunit of the multi-subunit Cullin-2 RING E3 ubiquitin ligase (CRL2VHL), which regulates intracellular concentrations of hypoxia inducible factors (HIFs) through a ubiquitin proteasome system (UPS) cascade. Strategic recruitment of CRL2VHL by bi- or trifunctional targeted protein degraders (e.g., PROTACs (R)) offers the prospect of promoting aberrant polyubiquitination and ensuing proteasomal degradation of disease-related proteins. Non-peptidic, l-hydroxyproline-bearing VHL ligands such as VH032 (1) and its chiral benzylic amine analog Me-VH032 (2), are functional components of targeted protein degraders commonly employed for this purpose. Herein, we compare two approaches for the preparation of 1 and 2 primarily highlighting performance differences between Pd(OAc)2 and Pd-PEPPSI-IPr for the key C-H arylation of 4-methylthiazole. Results from this comparison prompted the development of a unified, five-step route for the preparation of either VH032 (1) or Me-VH032 (2) in multigram quantities, resulting in yields of 56% and 61% for 1 and 2, respectively. Application of N-Boc-l-4-hydroxyproline rather than N-tert-butoxycarbonyl to shield the benzylic amine during the coupling step enhances step economy. Additionally, we identified previously undisclosed minor byproducts generated during arylation steps along with observations from amine deprotection and amidation reaction steps that may prove helpful not only for the preparation of 1 and 2, but for other VHL recruiting ligands, as well. Step economical routes for the multigram preparation of popular VHL E3 ligase recruiting ligands.
引用
收藏
页码:17077 / 17090
页数:14
相关论文
共 30 条
  • [21] The E3 ubiquitin-protein ligase MDM2 is a novel interactor of the von Hippel–Lindau tumor suppressor
    Antonella Falconieri
    Giovanni Minervini
    Raissa Bortolotto
    Damiano Piovesan
    Raffaele Lopreiato
    Geppo Sartori
    Maria Pennuto
    Silvio C. E. Tosatto
    Scientific Reports, 10
  • [22] Role of the C-terminal α-helical domain of the von Hippel–Lindau protein in its E3 ubiquitin ligase activity
    Martin D Lewis
    Ben J Roberts
    Oncogene, 2004, 23 : 2315 - 2323
  • [23] Multiple splice variants of the human HIF-3α locus are targets of the von Hippel-Lindau E3 uhiquitin ligase complex
    Maynard, MA
    Qi, H
    Chung, J
    Lee, EHL
    Kondo, Y
    Hara, S
    Conaway, RC
    Conaway, JW
    Ohh, M
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (13) : 11032 - 11040
  • [24] Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein
    Corn, PG
    McDonald, ER
    Herman, JG
    El-Deiry, WS
    NATURE GENETICS, 2003, 35 (03) : 229 - 237
  • [25] Diverse effects of mutations in Exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity
    Hansen, WJ
    Ohh, M
    Moslehi, J
    Kondo, K
    Kaelin, WG
    Welch, WJ
    MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (06) : 1947 - 1960
  • [26] Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel–Lindau protein
    Paul G Corn
    E Robert McDonald
    James G Herman
    Wafik S El-Deiry
    Nature Genetics, 2003, 35 : 229 - 237
  • [27] Structure-Guided Design and Optimization of Small Molecules Targeting the Protein Protein Interaction between the von Hippel- Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
    Galdeano, Carles
    Gadd, Morgan S.
    Soares, Pedro
    Scaffidi, Salvatore
    Van Molle, Inge
    Birced, Ipek
    Hewitt, Sarah
    Dias, David M.
    Ciulli, Alessio
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (20) : 8657 - 8663
  • [28] Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel-Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay
    Lin, Wenwei
    Li, Yongtao
    Yang, Lei
    Chen, Taosheng
    ACS OMEGA, 2021, 6 (01): : 680 - 695
  • [29] Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyI)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyppyrrolidine-2-carboxamide (VH298)
    Soares, Pedro
    Gadd, Morgan S.
    Frost, Julianty
    Galdeano, Carles
    Ellis, Lucy
    Epemolu, Ola
    Rocha, Sonia
    Read, Kevin D.
    Ciulli, Alessio
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (02) : 599 - 618
  • [30] Disturbed Flow Increases UBE2C (Ubiquitin E2 Ligase C) via Loss of miR-483-3p, Inducing Aortic Valve Calcification by the pVHL (von Hippel-Lindau Protein) and HIF-1 (Hypoxia-Inducible Factor-1) Pathway in Endothelial Cells
    Esmerats, Joan Fernandez
    Villa-Roel, Nicolas
    Kumar, Sandeep
    Gu, Lina
    Salim, Md Tausif
    Ohh, Michael
    Taylor, W. Robert
    Nerern, Robert M.
    Yoganathan, Ajit P.
    Jo, Hanjoong
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (03) : 467 - 481